O
CDNA icon

OrbiMed’s CareDx CDNA Stock Holding History

OrbiMed’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-827,600
Closed -$29.8M – 126
2019
Q2 		$29.8M Hold
827,600
– – 0.46% 52
2019
Q1 		$26.1M Buy
+827,600
New +$24.1M 0.4% 62

Other funds holding CDNA

FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

OrbiMed's CDNA Position: Q3 2019 in Review

OrbiMed sold out of CareDx (CDNA) in Q3 2019, closing a stake of 827,600 shares — an estimated $29.8M sold.

OrbiMed first reported a position in CDNA in Q1 2019 and held it in 2 quarters. The position peaked at $29.8M in Q2 2019. 174 funds tracked by Wall St. Rank hold CDNA as of Q3 2019.

  • OrbiMed reported no remaining CareDx position as of Q3 2019 after selling out during the quarter.
  • OrbiMed sold 827,600 CareDx shares in Q3 2019, an estimated $29.8M.
  • OrbiMed first reported a position in CareDx in Q1 2019 and held it in 2 quarters.
  • OrbiMed's CareDx position peaked at $29.8M in Q2 2019.
  • 174 funds tracked by Wall St. Rank held CareDx as of Q3 2019.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.